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Abstract We describe the neurological, electrophysiologi-
cal, and genetic features of autosomal dominant distal
hereditary motor neuronopathy (HMN) in a three-
generation Dutch family, including 12 patients with distal
muscle weakness and atrophy. The severity of disease
ranged from disabling muscle weakness to a subclinical
phenotype. Neurologic exams of nine patients and nerve
conduction studies (NCS) and myography in five endorsed
the variable presentations of HMN in this family, including
patients with only lower (four), upper (one), or both upper
and lower extremities involvement (four). Asymmetrical or
strictly unilateral disease was noted in three patients. Three
also showed pyramidal features. A genome-wide search
combining SNP arrays (250K) with parametric linkage
analysis identified a novel locus on chromosome 16p
(mLOD=3.28) spanning 6 Mb (rs6500882–rs7192086).
Direct sequencing excluded mutations in the SIMPLE/
LITAF gene (mapping to the 16p locus) and identified a
pathogenic mutation (p.N88S) in BCLS2 (11q12–q14). All
12 affected relatives had the BSCL2 mutation and the
chromosome 16p haplotype and showed features of motor
neuron degeneration. One patient had a very mild pheno-
type with bilateral pes cavus, normal concentric needle
electromyography but signs of motor neuron involvement
at electrophysiological muscle scan (EMS). Similar EMS
abnormalities in addition to abnormal NCS and myography
were observed in a clinically unaffected person (carrying
only the 16p haplotype). These results expand the clinical
spectrum of HMN and suggest a digenic inheritance of
H M Ni nt h i sf a m i l yw i t haBSCL2 mutation and a
chromosome 16 locus likely contributing to the phenotype.
Keywords Distalhereditarymotorneuronography.
Genome-widescan.Novellocus.Electrophysiological
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Introduction
Distal hereditary motor neuronopathy (HMN) is defined by
progressive muscle wasting and weakness without clinical,
electrophysiological, or morphological sensory involve-
ment due to anterior horn cell degeneration and is also
referred to as the spinal subtype of hereditary motor and
sensory neuropathy (HMSN) or Charcot–Marie–Tooth
disease (CMT) [1–3]. According to clinical findings, age
at onset, and mode of inheritance, seven subtypes of HMN
have been defined (HMN I–VII) [2, 4]. A genetic
classification of HMN is gradually evolving with the
identification of eight genes and 14 loci, associated with
distal HMN (Table 1)[ 2, 3, 5]. Several of these genes are
also associated with HMSN subtypes, hereditary motor
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cating an overlapping clinical spectrum. For instance,
mutations within the N-glycosylation site of BSCL2
(Bernardinelli–Seip congenital lipodystrophy)g e n ea r e
believed to cause a gain of function with accumulation of
unfolded protein in the endoplasmatic reticulum leading to
aggregate formation and neurodegeneration. These muta-
tions are associated with HMN as well as Silver syndrome,
an autosomal dominant spastic paraparesis with marked
atrophy of the hand muscles [6, 7]. The senataxin gene
(SETX), primary associated with autosomal dominant
juvenile amyotrophic lateral sclerosis (ALS4) and spastic
paraplegia without neuropathy (SPG19), has now also been
associated with distal HMN with pyramidal features [3, 8].
Nonsense mutations in senataxin cause ataxia-oculomotor
apraxia type 2 (AOA2), a neurodegenerative disorder with
cerebellar ataxia and severe axonal neuropathy [9]. Fur-
thermore, mutations in genes encoding small heath shock
protein (HSP1, HSP8) were reported in HMN type 2 as
well as in two axonal HMSN subtypes, CMT2F and
CMT2L. HMN type V and CMT2D, both predominantly
involving the hands, appeared to be allelic disorders, with
mutations in the glycil tRNA synthetase (GARS) gene [2, 4].
The pathogenic mechanism involved with these different
genetic forms of HMN are not well understood and suggest
disruption of a variety of cellular processes, including
protein misfolding, RNA/DNA transcription, axonal trans-
port, and endoplasmatic reticulum stress.
We present the neurological and electrophysiological
characteristics of autosomal dominant HMN in a large
Dutch family, displaying variability in localization (with a
hand type and a foot type) and co-occurrence of pyramidal
signs as well as a wide range in severity of distal muscle
weakness. The influence of genetic and/or environmental
modifiers has been suggested previously to explain the
clinical variability of HMN within families or carriers of a
specific mutation [4, 10, 11]. We combined the high-
throughput SNP array (250K) technology with parametric
linkage analysis and direct sequencing and identified a
novel HMN locus on chromosome 16p segregating with a
mutation in the BSCL2 gene previously associated with
HMN/Silver syndrome. Our results suggest that the novel
locus on chromosome 16 may contain a gene modifying
BSCL2-associated disease.
Patients and methods
Patients
Fifteen members of a Dutch three-generation family were
evaluated clinically by one neurologist (EB). The pedigree is
depicted in Fig. 1. Nine family members (four men, five
women) were considered to be definitely affected. Two
individuals, who were reported to be affected (II:3, III:8) could
not be examined; however, we were able to obtain medical
records confirming the diagnosis. DNA samples of these two
patients as well as a sample from stored DNA of a deceased
relative who was also reported to be affected (II:1) were
obtained. Three asymptomatic relatives did not have HMN
Table 1 Classification of distal hereditary motor neuronopathy
HMN subtype (alias) Locus Gene Inheritance Clinical hallmarks
I Unknown Unknown AD Juvenile onset
II (CMT2L) 12q24.3 HSP22 AD (Early)-adult onset
(CMT2F) 11q11-q21 HSP27 AD (Early)-adult onset
III 11q13 Unknown AR Early-adult onset, slowly progressive
IV 11q13 Unknown AR Juvenile onset, severe course, paralysis diaphragm
V (CMT2D) 7p15 GARS AD Upper limb predominance, pyramidal features may occur
(Silver syndrome) 11q12–q14 BSCL2 AD Prominent atrophy of hands, spasticity of lower limbs
VI (SMARD1) 11q13.2–13.4 IGHMBP2 AR Infantile onset, severe course, involvement diaphragm
(SMA-RD: respiratory distress)
VII 2q14 Unknown AD Adult onset, vocal cord paralysis
VII 2p13 DCTN1 AD Adult onset, vocal cord paralysis, facial weakness
n.a. (ALS4) 9q34 SETX AD Early onset, pyramidal features
n.a. (HMN-Jerash) 9p21.1-p12 Unknown AR Juvenile onset, pyramidal features
n.a. (congenital SMA) 12q23-q24 Unknown AD Congenital, non-progressive, contractures
n.a 1p36 PLEKHG5 AR Childhood onset, severe course
DSMAX. Xq13.1-q21 Unknown X-linked Juvenile onset
HMN hereditary motor neuronopathy, CMT Charcot–Marie–Tooth, ALS amyotrophic lateral sclerosis, SMA spinal muscular atrophy, AD
autosomal dominant, AR autosomal recessive, n.a. not applicable
290 Neurogenetics (2009) 10:289–297featuresupon neurologic examination.Inthreeclinicallyaffected
(II:5, II:7, and III:1) and one clinically unaffected relative (II:9),
nerve conduction studies (NCS) and concentric needle myog-
raphywereperformed,includinganelectrophysiologicalmuscle
scan (EMS) in II:5 and II:9. An EMS is a detailed stimulus
intensity—compound muscle action potential (CMAP) ampli-
tude response curve—representing the contribution of individ-
ual motor units (MUs) to the CMAP. This test was recently
developed in our clinic and can detect large MUs due to chronic
reinnervation, which might be missed in concentric needle
examination [12]. Medical records of two additional patients
(III:4 and IV:1) provided results of NCS studies.
Genotyping
Genomic DNA was isolated from peripheral blood using the
Puregene DNA kit (Gentra Systems) [13]. The genome-wide
s e a r c hw a sc o n d u c t e di n1 5f a m i l ym e m b e r s( 1 1a f f e c t e d )
using the Affymetrix GeneChip Mapping 250K Nsp Array
containing 262,264 SNP markers. Samples were processed
according to the manufacturer’s instructions (Affymetrix
GeneChip Mapping Assay). Affymetrix GCOS software
v1.4, GTYPE software v4.1, and the dynamic model
algorithm were used to derive SNP genotypes. Finally, the
BRLMM algorithm was used to improve overall performance.
Linkage analysis and locus identification
The statistical package EasyLinkage Plus v5.02 designed to
perform automated linkage analyses using large-scale SNP
data was used to perform all analyses [13]. PedCheck
(v1.1) and Merlin (v1.0) were used to search for unusual
patterns of Mendelian inheritance consistent with potential
genotyping errors or unusual double recombinants. All
SNPs showing inconsistency in transmission were removed
from further analyses. Allegro v1.2c software (incorporated
in the EasyLinkage Plus v5.02 package) was used to
perform fully automated single point and multipoint
linkage analysis. LOD scores were obtained using a
dominant model of inheritance, with a penetrance of
98%, a phenocopy rate of 1:1,000, and a disease allele
frequency of 1:10,000. Allele frequencies of all geno-
typed SNPs (derived from Caucasian control individuals),
map order, and genetic inter-SNPs distances were taken
from the Affymetrix website (Marshfield sex-averaged
genetic map).
An “affected only” linkage analysis was performed:
Individuals with a definite clinical diagnosis were included
in the analysis as “affected”. All relatives with insufficient
clinical data or no clinical evidence of disease were
classified as “diagnosis unknown”, regardless of their age.
Fig. 1 Pedigree of the family with distal HMN. Filled symbols
indicate affected individuals. A question mark identifies individuals
with “undetermined” phenotype. Below each individual, numbered
alleles correspond to each of the microsatellite markers: D11S905
(57.4 cM), D11S4191 (64.9 cM), D11S987, (72.2 cM), and D11S1314
(78.75 cM). Marker order and positions are according to the Marsh-
field sex-averaged genetic map. A black bar indicates the shared
haplotype. BSCL2 is located between D11S4191 and D11S987. A
positive (plus signs) or negative (minus signs) sign indicate presence
or absence of p.N88S BSCL2 mutation. The most likely (non-
recombinant) haplotype for III:3 would be (5–3–5–3), indicating no
linkage to the BSCL2 region. However, she was also carrying the p.
N88S mutation. Several single and double recombinations are
displayed
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predefined spacing of 0.2 to 0.4 cM. Then, single
chromosomes showing positive linkage signals were inde-
pendently analyzed under the same conditions and haplo-
types were constructed. Graphical visualization of
haplotypes was performed with HaploPainter v029.5 [14].
Microsatellite markers mapping to the identified “can-
didate” genomic regions were selected. PCRs were
performed with M-13 tailed primers and addition of
fluorescent labels (FAM, VIC, or NED). Products were
run on an ABI Prism 3100 genetic sequencer (Applied
Biosystems) and analyzed using the GeneMapper software
v.3.0 (Applied Biosystems).
Sequencing analysis
Direct sequencing of the entire coding region and the exon–
intron boundaries of candidate genes was undertaken using
PCR primers designed by Primer3 software [15]. Amplified
PCR products were purified and sequenced using BigDye
Terminator chemistry v3.1 on an ABI Prism 3100 genetic
analyzer (Applied Biosystems). Sequences were aligned
and compared with consensus sequences obtained from the
human genome databases, using SeqScape v2.5 [16].
Quantitative PCR
Quantitative PCR was performed on genomic DNA and
cDNA from several patients and controls. For each
experiment, two housekeeping genes were used as refer-
ence genes, and two different assays were performed
covering exons 2 to 4 of the LITAF/SIMPLE gene. All
samples were done in triplicate, and experiments were
repeated at least twice. Reactions were performed using the
iTaq Sybr Green supermix with ROX (Bio-Rad) in a 7300
real-time PCR machine from Applied Biosystems.
Results
Clinical findings
The results of the neurologic exams and electrophysiolog-
ical studies are summarized in Tables 2 and 3. The proband
Table 2 Clinical findings in nine patients from the Dutch family with distal motor neuronopathy
Patient
(age)
Age at
onset
Localization of
first symptoms
Weakness arms
(right/left)
Atrophy arms
(right/left)
Weakness legs
(right/left)
Atrophy legs
(right/left)
Pyramidal
signs
Pes cavus
II:5(73) ~10 Feet −/−− /− +/+ −/−− P
II:7(69) ~10 Feet −/−− /− +/++ +/++ − P
III:1(49) 10 Feet −/−− /− ++/++ ++/+ P P
III:3(49) 16 Right hand ++/+ ++/+ +/−− /− P −
III:4(43) 12 Hands ++/++ ++/++ +/+ −/− P −
III:6(46) ~10 Feet −/−− /− ++/++ +/+ − P
IV:1(16) 14 Hands +/+ +/+ +/+ −/−− −
IV:2(12) 12 Hands +/+ +/+ −/−− /−− −
IV:3(16) 11 Feet +/+ +/+ ++/++ ++/++ − P
− absent, + mild to moderate (MRC grade 4), ++ moderate to severe (MRC grade 3 or below), P present
Table 3 Results of nerve conduction studies
Patient Localization of
first symptoms
CMAP amplitude arms
(mV, n medianus)
NCV arms
(m/s, n medianus)
CMAP amplitude
legs (mV, n peroneus)
NCV legs
(m/s, n peroneus)
Myography
II:5 Feet N (5,5) N (56) N (5,4) N (51) N
II:7 Feet N (9,2) ↓ (47) Absent n.a. Reinnervation
II:9 na ↓↓ (1,9) N (61) N (5,6) N (56) Giant potentials
III:1 Feet N (10.1) N (56) ↓↓↓ (0,4) ↓ (31) N
III:4 Hands U ↓↓ (39) U N (45) U
IV:1 Hands ↓/absent (0-0,7) N (56) ↓ (2,1) N (51) Giant potentials
EMG in patient III:4 and IV:1 were performed in other clinics
na not applicable, N normal, ↓ mild reduction, ↓↓ moderate reduction, ↓↓↓ severe reduction, U unknown
292 Neurogenetics (2009) 10:289–297(III:1), evaluated at the age of 49 years, reported slowly
progressive weakness and stiffness of the legs from the age
of 10 years: At age 30, she needed orthopedic shoes, and at
age 48 years, she was walking with a cane. Her deceased
mother (II:1) was diagnosed previously with early onset
“neurogenic muscle atrophy,” predominantly affecting the
upper limbs. Neurological examination of III:1 displayed a
combination of spastic and steppage gait. There was a
moderate asymmetrical paresis of the distal legs, most
prominent in the ankle dorsiflexors with bilateral pes cavus.
Hypertonia and hyperreflexia of the lower limbs was found,
with bilateral Babinski’s sign. There was no sensory
involvement, and examination of the upper extremities
was normal. NCS showed markedly reduced CMAP
amplitudes in the lower extremities, with some slowing of
conduction velocity. Sensory NCS and concentric needle
electromyography (EMG) were normal (Table 3). MRI
imaging of the brain revealed no abnormalities.
A maternal uncle of the proband (II:7) had never been
able to walk on heels or toes. From the age of 54, he had
noticed a left foot drop. Examination at age 69 revealed
asymmetrical weakness of the ankle dorsiflexors, with
bilateral pes cavus, but without pyramidal features. NCS
showed reduced to absent CMAP amplitudes in the lower
extremities (Table 3). His son (III:8) was reported with
weakness and wasting of the hand musculature from the
age of 6 years.
Upon the neurological examination of three reported
asymptomatic maternal aunts (II:5, II:9, and II:10), in II:5
(aged 73 years), we found bilateral pes cavus and mild
weakness of the ankle dorsiflexors without pyramidal signs
(Fig. 3). She confirmed that from her teens, she had never
been able to wear boots due to her foot deformity, but she
had not experienced functional restrictions. Motor NCS and
myography were normal. Sensory NCS of the right distal
median nerve was indicative of a sensory carpal tunnel
syndrome (Table 3). The EMS, recorded at the abductor
pollicis brevis muscle, showed several steps up to 500 µV,
indicating the presence of large MUs, probably in combi-
nation with a decreased number of functional MUs. This is
representing a chronic denervation–reinnervation process.
Her sisters II:9 and II:10 showed no neurological abnor-
malities at age 70. In II:9, the distal CMAP amplitude of the
right median nerve was reduced, and myography showed a
markedly reduced maximal recruitment pattern in the
abductor pollicis brevis muscle with giant MU potentials
up to 6–7 mV (Table 3). The EMS showed a similar pattern
as in her clinically affected sister II:5.
Neurological examination of the asymptomatic sister
III:2 of the proband (at age 49) was normal. A younger
sister (III:3) of the proband, examined at age 49 years, had
noticed a non-disabling weakness of the right hand since
the age of 16 years and a mild unilateral foot drop
beginning 2 years ago. Neurological examination displayed
weakness of intrinsic muscles of the right hand, with
atrophy and clawing of the fingers. There was mild
weakness of the right ankle dorsiflexors and hyperreflexia
of the right leg with a Babinski’s sign.
Onset of hand dysfunction in the youngest sister (III:4)
of the proband was at the age of 12 years, and she had
noticed a mild gait disturbance beginning several years ago.
Neurological examination at age 43 revealed weakness and
atrophy of the hand muscles, most prominent in the thenar
and first dorsal interosseus muscles (with sparing of the
hypothenar muscles: “split-hand” type atrophy), with
clawing of the fingers. There was mild weakness of ankle
dorsiflexors, without atrophy or pes cavus. Hyperreflexia of
the legs with bilateral Babinski’s signs were present.
Previous electrophysiological studies at age 24 showed
mild slowing of motor nerve conduction in the arms
(Table 3).
A maternal uncle of the proband (II:3) and his son (III:6)
both reported a non-disabling childhood onset bilateral pes
cavus. Neurological examination of III:6 at the age of
46 years revealed distal weakness and atrophy of the legs,
most pronounced at the ankle dorsiflexors with a steppage
gait without pyramidal features.
Both IV:1 and IV:2, examined at the age of 16 and
12 years, respectively, displayed a split-hand type atrophy
of the hand musculature, similar to the symptoms of their
mother (III:4). These two patients lacked pyramidal signs.
IV:1 also displayed mild weakness of the ankle dorsiflexors.
NCS in IV:1 at age 14 showed reduced to absent CMAP
amplitudes in upper and lower extremities. Myography of
tibialis and first interosseus dorsalis muscles showed giant
MU potentials (Table 3). Medical history of IV:1 reported
seizures from the age of 2 to 7 years. IV:2 was diagnosed
with a disorder in the attention-deficit hyperactivity
spectrum.
Onset of symptoms in IV:3 was at the age of 11 years.
Neurological examination at age 16 revealed mild weakness
and atrophy of the intrinsic hand muscles and severe
weakness of the opponens pollicis muscles and the ankle
dorsiflexors, with bilateral pes cavus, without pyramidal
features.
Analysis of genes previously associated with HMN
Direct sequencing of the coding region of the GARS, HSP1,
HSPB8 and Neurofilament Protein, Light polypeotide
(NEFL) genes excluded mutations in the index patient
(Neurogenetics Laboratory, Amsterdam). The Senataxin
(SETX) locus on 9q34 was excluded by haplotype analyses
using eight affected relatives (data not shown). Transmis-
sion of microsatellite markers around the Seipin (BSCL2)
locus on 11q13 indicated that all but one of the 12 patients
Neurogenetics (2009) 10:289–297 293in this family shared the same haplotype, making linkage to
this locus unlikely, since this would require the occurrence
of at least one double recombinant and several single
recombinations in one patient and her relatives (Fig. 1).
Although neither the haplotype nor the linkage analysis
(LOD score of 2.1, Table 4) supported a causative role of
BSCL2, we decided to pursue investigations of this gene.
The phenotype of this family was similar to previously
described Dutch families with Silver syndrome [6]. Se-
quencing of exon 3 of the BSCL2 gene detected a known
heterozygous c.263A > G (p.N88S) mutation [7] present in
all 12 patients but not found in the three asymptomatic
relatives II:10, III:2, and in II:9 (with abnormal electro-
physiological and EMS studies).
Linkage analysis and haplotyping
We performed a genome-wide linkage analysis in 15
relatives, including 11 patients, using the Affymetrix
250 K Nsp arrays. After setting inter-marker spacing to
0.2, 0.3, and 0.4 cM, a total of 15,473, 10,622, and 8,090
SNPs were selected by the program for further linkage
analyses, respectively. When multipoint linkage analyses
were performed, several genomic regions displayed LOD
scores above 2 (Table 4). The highest LOD scores (2.7) were
observed on chromosome 16 and 17. We tested microsatellite
markers covering these regions (D16S404, D16S519,
D16S3075, D16S680, D16S3103 and D17S1857, D17S798,
D17S1880, D17S1850, D17S1868). Haplotype analysis
revealed that all 12 patients were sharing the same “disease”
haplotype on chromosome 16p (Fig. 2), indicating complete
segregation of HMN with the chromosome 16 locus. Based
on the SNP data, the haplotype on 16p13.3–p13.12 spans
approximately 14.6 cM (6 Mb) between the SNPs rs6500882
(6.9 Mb, SNP_A2078682) and rs7192086 (12.96 Mb,
SNP_A1813744). Multipoint linkage analyses using the
microsatellite data yielded a significant mLOD of 3.28 for
chromosome 16p (using the same genetic model described
before).
The identified chromosome 16p locus (from 6.9 Mb
until 12.96 Mb) contains 49 genes. One of them, the LITAF/
SIMPLE gene, associated with CMT1C, was an obvious
candidate for further analysis. Direct sequencing of the four
exons plus part of the 5′ and 3′ UTR of the gene displayed
only two DNA variants in the coding region of the gene
Ile92Val (rs4280262), a known polymorphism and a novel
silent change (p.Asn110Asn). Both variants were not co-
segregating with the phenotype in this family and therefore
are likely not pathogenic.
We then investigated whether copy number variants
within LITAF/SIMPLE could have a role in causing the
HMN phenotype. We performed quantitative real-time PCR
on genomic DNA from four patients (III:1, III:3, III:4, and
IV:1) and compared them to unaffected family members
and controls. No evidence for deletions or duplication was
found along the coding region of LITAF. Quantitative real-
time PCR performed on cDNA detected upregulation
(3-fold increase) in LITAF levels in two patients (III:1 and
III:4) and in one unaffected (III:2) family member, while
two other patients (III:6 and IV:3) and two asymptomatic
relatives (II:9 and II:10) had normal levels. These results
showed that changes in LITAF expression do not influence
disease in this family.
Chromosome Inter-SNP spacing
0.2cM 0.3cM 0.4cM
Region (cM) mLOD Region (cM) mLOD Region (cM) mLOD
3 125−126 2.6 −− 125−126 2.4
4 13 2.1 89−93 2.7 −−
81 1 8 −121 2.5 −− 91−92 2.2
99 8 −101 2.6 −− 97−101 2.5
11 61−65 2.1 53−54 2.1 −−
16 15−30 2.7 17−31 2.7 15−30 2.7
17 46−49 2.7 46−49 2.7 42−49 2.7
17 57−58 2.3 56−58 2.7 −−
17 63−64 2.6 −− 63−64 2.6
Table 4 Summary of the
genome-wide linkage analyses
(250 K Nsp Affymetrix)
cM centimorgan, mLOD maxi-
mum multipoint LOD score
Fig. 2 Pedigree of family with HMN showing SNP haplotypes
corresponding to the 16p13.3–p13.12 region. Filled symbols indicate
affected individuals. A question mark identifies individuals with
undetermined phenotype used in the analysis. Informative SNPs with
a spacing of 0.3 cM has been used in this figure. Haplotypes
corresponding to individuals I:1, I:2, II:2, and II:8 were reconstructed
by the program (Allegro). A dark brown bar identifies the disease
haplotype. Recombinations occurring in III:8 and III:6 are delimiting
the area of 14.6 cM to approximately 12 cM (6 Mb) between
SNP_A2078682 or rs6500882 (not depicted in figure due to the
selected spacing) and SNP_A1813744 or rs7192086
b
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We described an extensive family with autosomal dominant
distal HMN showing a wide range in the severity and
localization of neuromuscular symptoms. In nine examined
patients, distribution of muscle weakness and atrophy
included involvement of predominantly the feet (n=4), the
hands (n=1), or both upper and lower extremities (n=4),
often with split-hand type atrophy. Co-occurrence of
pyramidal features was observed in three patients. In two
patients, muscle involvement was asymmetric, and in one,
strictly unilateral muscle weakness and atrophy was
observed. Severity of the disease ranged from adolescent
patients with disabling muscle weakness to an elderly
patient with only mild weakness of the ankle dorsiflexors
and bilateral pes cavus (II:5) (Fig. 3). The asymmetrical
involvement of muscle weakness, the pyramidal signs, and
the absence of sensory deficits indicate spinal anterior horn
cells involvement, as was supported by electrophysiology
showing signs of chronic motor axonal injury with normal
sensory conduction.
The recently introduced and promising technique of the
EMS [12] showed signs of chronic motor neuron involve-
ment in the upper extremities in one patient (II:5) with a
relatively mild phenotype, whereas motor NCS studies and
myography were normal in this patient. The EMS may
therefore be considered as a sensitive technique to detect
subtle or even subclinical motor neuron dysfunction. This
should be confirmed with further NCS and EMS studies in
affected and healthy relatives.
Fig. 3 Pes cavus in individual II:5
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Neurogenetics (2009) 10:289–297 295In this family, one of the two reported mutations in exon
3 of the BSCL2/Seipin gene associated with HMN and
Silver syndrome was identified in all 12 clinically affected
individuals. Functional (in vitro) evidence is indicating that
the N88S and S90L mutations destroy a predicted N-
glycosylation site of the protein at positions 88–90,
resulting in aggregates formation, cell death, and neuro-
degeneration [7, 17]
Vande Warrenburg etal. describe two other Dutch families
with the same c.236A > G mutation, showing a similar age at
onset and intrafamilial variability in localization as observed
in our family [6]. However, the unilateral involvement
observed in this study has not been described previously.
As illustrated in Tables 2 and 3, in the majority of the
patients, onset of clinical features occurs at age 10–16 years.
However, the three patients of the youngest generation seem
to display a severe phenotype considering their age, mostly
with bilateral involvement of both hand and feet. This
suggestion of possible anticipation could not be explained by
the 16p haplotype shared by all affected relatives.
Auer-Grumbach et al. described the variability of the
clinical phenotype in 90 patients with the p.N88S mutation,
indicating that approximately 25% of the patients were not
affected or were subclinically affected, sometimes only
displaying NCS abnormalities. In addition, patients with
this specific mutation have been diagnosed as a hand-type
d-HMN (31.1%), classical Silver syndrome (14.5%), CMT-
phenotype (20%), or pure spastic paraparesis (10%) [18].
This extreme variability in phenotype in a disorder
related so far to only two mutations in the BSCL2 gene is
remarkable and suggests influence of genetic or environ-
mental modifiers. The digenic inheritance of the pathogenic
mutation in the BSCL2 gene and the locus on chromosome
16p suggests that the latter may contain a gene-modifying
disease expression in this family. The 16p region was
shared by 14 relatives: 12 definite patients and two
clinically unaffected twin sisters II:9 and II:10 without the
p.N88S mutation. Electrophysiological studies in the
unaffected II:9 did show motor neuron damage with a
diminished CMAP amplitude of the median nerve and signs
of reinnervation in myography. These abnormalities are not
likely to be attributable to an asymptomatic carpal tunnel
syndrome because sensory NCS of the median nerve were
normal. Furthermore, the EMS in II:9 showed similar signs
of motor neuron involvement as in her mildly affected sister
II:5, who is carrying both the BLCS2 mutation and the
chromosome 16p haplotype. These findings suggest that the
16p locus may be associated with attenuated forms of
HMN. Alternatively, these observations may indicate that
the 16p locus is not sufficient for disease causing but has
additive pathogenic effect.
An obvious candidate gene, the LITAF/SIMPLE gene,
maps to the 16p region. The gene was associated with a
demyelinating HMSN-subtype (HMSN1C). Also, a CMT2
phenotype, displaying asymmetric distal muscle weakness
and normal NCV, has been associated with a LITAF
mutation [19]. In our family, mutations in the coding region
of the LITAF/SIMPLE gene were excluded by direct
sequencing, and no copy number variants (genomic DNA)
were detected. Differences in gene expression (RNA-
cDNA) were found but were not related to disease status.
TheIngenuitydatabase(IngenuitySystems,www.ingenuity.
com) identified 33 of the 49 genes located on the chromosome
16 locus. Among those 33 genes, there are some possible
candidate genes involved in DNA damage response and
double-strand break repair pathways previously associated
with neurodegeneration (i.e., CARHSP1 (calcium-regulated
heat-stable protein), GRIN2A (N-methyl-D-aspartate glutamate
receptor 2A), SOCS1 (suppressor of cytokine signaling 1), SNN
(stannin), and TNFRSF17 (tumor necrosis factor receptor
superfamily, member 17), A2BP1 (ataxin 2-binding protein 1),
CIITA (class II, major histocompatibility complex, transactiva-
tor), and RSL1D1 (ribosomal L1 domain containing 1)).
In conclusion, clinical and molecular studies of a large
Dutch family with HMN detected a concomitant pathogenic
mutation p.N88S in the BSCL2 gene and linkage to a locus
on chromosome 16p associated with a wide variation in
severity and presentation of the neuromuscular features.
The role of the locus on chromosome 16p in HMN
pathogenesis remains to be elucidated; it may act as a
disease modifier, possibly explaining the phenotypic vari-
ability ranging from strictly neuropathic weakness to a
spastic paraplegia.
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